CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for gastrointestinal and metabolic disorders, announced today the completion of the last patient visit of the Trizytek Phase 3 efficacy trial. In this trial, Altus is evaluating the efficacy of an oral, non-porcine enzyme replacement therapy for cystic fibrosis patients with exocrine pancreatic insufficiency. Derived from recombinant technology, Trizytek [porcine-free enzymes] is a consistent, stable and pure combination of three active enzymes in a fixed-ratio that is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.
